The iShares
NASDAQ Biotechnology Index (NASDAQ: IBB) is up about 10%.
BIOTECH STOCKS NEAR 2019 LOWS: The iShares
Nasdaq Biotechnology Index, an ETF that tracks the stocks of biotech group, is trading relatively unchanged since early January of 2019.
Cooley is counsel to more than 1400 public and private life sciences companies across the globe and counsel to more than 50% of the companies on the
NASDAQ Biotechnology Index.
The
Nasdaq Biotechnology Index, often used as a barometer for investor sentiment about drug prices, was up 0.1 percent after rising as much as 0.5 percent earlier.
The SandP healthcare index ended 1.47 percent higher, while the
Nasdaq Biotechnology index rallied 2.68 percent.
(NASDAQ: GLYC) will be included in the
NASDAQ biotechnology Index, the company said.
The
Nasdaq Biotechnology Index is up 29% since the start of the year, and outpacing other indices.
Even with the recent downturn, the
NASDAQ Biotechnology Index (IBB) has increased 250% in the past five years.
The
Nasdaq biotechnology index was up about 2 percent.
UBIO seeks to provide 3x and ZBIO seeks to provide -3x the daily performance of the
Nasdaq Biotechnology Index, before fees and expenses.
The
Nasdaq Biotechnology Index slipped 2.2 percent, paring its best quarterly gain since 2013.
After a year of remarkable gains--accentuated by a near-record number of initial public offerings (IPOs) and 61 percent rise in the
NASDAQ Biotechnology Index (the gain is more than double the S&P 500's 26 percent growth in 2013)--biotech stocks have significantly lost their luster.
